Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute
ClinicalTrials.gov Identifier:
NCT01051570
First received: January 15, 2010
Last updated: August 9, 2014
Last verified: August 2014

January 15, 2010
August 9, 2014
February 2010
September 2013   (final data collection date for primary outcome measure)
Time to Progression (TTP) [ Time Frame: Every 3 cycles (cycle = 21 days) ] [ Designated as safety issue: No ]
Time to progression (TTP) [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01051570 on ClinicalTrials.gov Archive Site
  • Toxicity as Measured by NCI CTCAE v3.0 Criteria [ Time Frame: Day 1 of each cycle (every 21 days) ] [ Designated as safety issue: Yes ]
  • PSA Response Rate [ Time Frame: Day 1 of each cycle (every 21 days) ] [ Designated as safety issue: No ]
  • Association of TTP and PSA Response Rate With Correlative Markers (Phospho mTOR, pAKT, and p70S6) [ Time Frame: Archival tissue will be collected if available. Optional biopsies pre-treatment and 24 hours after first everolimus and carboplatin dose ] [ Designated as safety issue: No ]
  • Pharmacokinetics [ Time Frame: Samples will be collected Cycle 1, day 1, 2 & 8 and Cycle 2, Day 1 & 2 ] [ Designated as safety issue: No ]
  • Overall Survival [ Time Frame: After treatment, participants will be contacted every 3 months ] [ Designated as safety issue: No ]
  • Toxicity as measured by NCI CTCAE v3.0 criteria [ Designated as safety issue: Yes ]
  • PSA response rate [ Designated as safety issue: No ]
  • Overall survival [ Designated as safety issue: No ]
  • Association of TTP and PSA response rate with correlative markers (phospho mTOR, pAKT, and p70S6) [ Designated as safety issue: No ]
  • Pharmacokinetics [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
Phase II Trial of Carboplatin and Everolimus (RAD001) in Metastatic Castrate Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Chemotherapy.

RATIONALE: Drugs used in chemotherapy, such as carboplatin and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving carboplatin together with everolimus and prednisone may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving carboplatin together with everolimus and prednisone works in treating patients with metastatic prostate cancer that progressed after docetaxel.

OBJECTIVES:

Primary

  • To evaluate the time to progression (TTP) achieved with carboplatin and everolimus in patients with castrate resistant metastatic prostate cancer that progressed after docetaxel-based chemotherapy.

Secondary

  • To evaluate the safety of this regimen.
  • To assess the PSA response rate in patients treated with this regimen.
  • To evaluate the overall survival (OS) outcome in these patients.
  • To investigate the association of TTP and PSA response rate with correlative markers, such as phospho mTOR, pAKT, and p70S6.
  • To evaluate the pharmacokinetics of this regimen.
  • To explore the association of TTP, OS, and circulating tumor tumor cell count.

OUTLINE: Patients receive carboplatin IV over 30-60 minutes on day 1, oral prednisone twice daily on days on days 1-21, and oral everolimus once daily on days 2-21 of course 1 and on days 1-21 of subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Blood and tumor tissue samples are collected periodically for pharmacodynamic, pharmacokinetic, and biomarker analysis.

After completion of study treatment, patients are followed up every 3 months.

Interventional
Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostate Cancer
  • Drug: carboplatin
    AUC = 5 by Calvert's formula, day 1 of each 21 day cycle
    Other Name: Paraplatin®
  • Drug: RAD 001
    5 mg orally starting on Day 2 then continuous
    Other Names:
    • Afinitor®
    • Zortress
    • Everolimus
  • Drug: prednisone
    5 mg orally twice a day starting on Day 1 then continuous
    Other Names:
    • Deltasone
    • Liquid Pred
    • Meticorten
    • Orasone
    • Prednicen-M
    • Prednicot
    • Sterapred
    • Sterapred DS
  • Other: laboratory biomarker analysis
    Samples will be collected from archival tissue.
  • Other: pharmacological study
    Samples will be collected Cycle 1, day 1, 2 & 8 and Cycle 2, Day 1 & 2
Experimental: Carboplatin, RAD 001 & Prednisone

Carboplatin: AUC=4 by Calvert's formula (max dose 600 mg)*IV over 30-60 min, Day 1 of a 21 day cycle

RAD 001: 5 mg Orally daily, starting from Day 2 continuously

Prednisone 5 mg Orally twice daily, continuously

Interventions:
  • Drug: carboplatin
  • Drug: RAD 001
  • Drug: prednisone
  • Other: laboratory biomarker analysis
  • Other: pharmacological study
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
26
November 2013
September 2013   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed metastatic adenocarcinoma of the prostate
  • Objective disease progression or rising PSA despite androgen deprivation therapy and antiandrogen withdrawal (when applicable)
  • Progressed after ≥ 1 prior docetaxel-based chemotherapy regimen for metastatic disease

    • Patients with measurable disease* must have either rising PSA, increase in size of the lesion(s), or both

      • Patients with rising PSA as the only evidence of disease progression must demonstrate a rising trend with 2 successive elevations ≥ 1 week apart
    • Patients with no measurable disease must have a PSA ≥ 5 ng/mL or new areas of bony metastases on bone scan NOTE: *There is no minimum PSA requirement for patients with measurable disease
  • Documented to be castrate with a testosterone level of ≤ 0.5 ng/mL

    • Leuteinizing hormone-releasing hormone agonist therapy must be continued, if required to maintain castrate levels of testosterone
  • No uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases

PATIENT CHARACTERISTICS:

  • Zubrod performance status 0-1
  • ANC ≥ 1,500/mm^3
  • Hemoglobin ≥ 9.0 g/dL
  • Platelet count ≥ 100,000/mm^3
  • Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • Calculated creatinine clearance ≥ 50 mL/min OR serum creatinine ≤ 2 mg/dL
  • AST and/or ALT ≤ 2.5 times ULN if alkaline phosphatase normal OR alkaline phosphatase ≤ 4 times ULN if AST and/or ALT normal (for patients without documented bone metastases or for patients with liver metastases)
  • AST and/or ALT < 2.5 times ULN, without regard to alkaline phosphatase levels (for patients with documented bone metastases)
  • Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5 times ULN (in the case that one or both of these thresholds are exceeded, the patient is eligible only after initiation of appropriate lipid-lowering medication)
  • Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment
  • Willing and able to comply with this study
  • Able to ingest oral medication
  • No other malignancies except non-melanoma skin cancer or any other adequately treated cancer in complete remission for ≥ 2 years
  • No significant traumatic injury within the past 4 weeks
  • No active (acute or chronic) or uncontrolled severe infections
  • No severe and/or uncontrolled medical conditions or other conditions that could affect study participation, including the following:

    • NYHA class III-IV symptomatic congestive heart failure
    • Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within the past 6 months, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease
    • Severely impaired lung function as defined by spirometry and DLCO that is 50% of the normal predicted value and/or oxygen saturation that is ≤ 88% at rest on room air
    • Uncontrolled diabetes as defined by fasting serum glucose > 1.5 times ULN
    • Liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis
    • Known history of HIV seropositivity, hepatitis B or C
    • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
    • Active, bleeding diathesis
  • No known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to their excipients
  • No history of noncompliance to medical regimens
  • No uncontrolled diabetes mellitus

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • At least 1 prior docetaxel based regimen for metastatic disease

    • Docetaxel based combination therapy or docetaxel alone considered as 1 regimen
  • No more than 2 prior chemotherapy regimens for metastatic disease
  • No prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus)
  • At least 6 weeks since prior bicalutamide or nilutamide
  • At least 4 weeks since prior flutamide
  • More than 4 weeks since prior and no other concurrent investigational drugs
  • More than 4 weeks since prior and no other concurrent anticancer therapies (including chemotherapy, radiotherapy, or antibody-based therapy)
  • More than 4 weeks since prior and no concurrent major surgery (defined as requiring general anesthesia) and recovered
  • More than 1 week since prior and no concurrent immunization with attenuated live vaccines
  • No concurrent chronic, systemic treatment with corticosteroids or other immunosuppressive agents

    • Topical or inhaled corticosteroids are allowed
  • No concurrent prophylactic growth factors
  • Concurrent bisphosphonate therapy allowed
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01051570
CDR0000663630, P30CA022453, WSU-2009-087, NOVARTIS-WSU-2009-087
Yes
Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Principal Investigator: Ulka N. Vaishampayan, M.D. Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP